NCT05292898 is a Phase 1 clinical trial of LCAR-AIO Cells in Acute Lymphocytic Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT05292898?

NCT05292898 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT05292898?

Interventions in NCT05292898: LCAR-AIO Cells.

What condition does NCT05292898 study?

NCT05292898 studies Acute Lymphocytic Leukemia.

Is NCT05292898 still recruiting?

NCT05292898 is currently terminated. Last updated 3 June 2025.

Last reviewed 2025-06-03 · How we verify

NCT05292898

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Terminated Phase 1 Last updated 3 June 2025

What this trial tests

Phase 1 trial testing LCAR-AIO Cells in Acute Lymphocytic Leukemia in 10 participants. Terminated before completion.

Timeline

14 March 2022

Primary endpoint
10 January 2025

31 March 2025

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	14 March 2022
Primary completion	10 January 2025
Estimated completion	31 March 2025
Sites	2 locations across China

Drugs / interventions tested

LCAR-AIO Cells — full drug profile →

Conditions studied

Acute Lymphocytic Leukemia — all drugs for Acute Lymphocytic Leukemia →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

Adults 18 to 75, any sex, with Acute Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LCAR-AIO, a triple-targeted cell preparation targeting CD19/CD20/CD22, in patients with relapsed/refractory B-cell acute lymphocytic leukemia

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Multi-targeted immunotherapeutics to treat B cell malignancies.
Gambles MT, Yang J, Kopeček J. · · 2023 · cited 8× · PMID 37121515 · DOI 10.1016/j.jconrel.2023.04.048
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs.
Guo S, Xi X. · · 2025 · cited 7× · PMID 40069884 · DOI 10.1186/s40364-025-00755-5

Verify or expand the search:

Other recruiting trials for Acute Lymphocytic Leukemia

Currently open trials in the same condition.

NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
NCT07008885 — BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL · Phase 1, PHASE2 · recruiting
NCT06481735 — TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL · Phase 1, PHASE2 · recruiting
NCT06476665 — A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia. · active not recruiting
NCT06783816 — A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors · NA · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05292898 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 3 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05292898.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing